550.00GBp+4.27%Mkt Cap: 85.17M GBpP/E: —Last update: 2026-06-01
4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and non-viral vector solutions in Europe, the United States, and…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap85.17M GBp
Enterprise Value80.62M GBp
Revenue (TTM)1.69M GBp
Gross Profit630.00K GBp
Net Income (TTM)-12.33M GBp
Revenue/Share0.1090 GBp
Last Price550.00 GBp
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees—
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.28
PEG—
EV/EBITDA-4.84
EV/Revenue47.62
P/S48.25
P/B8.10
EPS (TTM)-1.09
EPS (Forward)-1.00
52W Range
0.000048% of range1150.00
52W High1150.00 GBp
52W Low0.0000 GBp
Profitability
Gross Margin67.52%
Oper. Margin-1784.59%
EBITDA Margin0.00%
Profit Margin-1321.86%
ROE-46.75%
ROA-27.57%
Growth
Revenue Growth-14.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-10.74M GBp
CapEx (TTM)1.57M GBp
FCF Margin-766.71%
FCF Yield-15.24%
Net Debt-1.30M GBp
Net Debt/EBITDA0.08
Balance Sheet
Debt/Equity0.58
Current Ratio7.31
Quick Ratio6.40
Book Value/Sh0.6510 GBp
Cash/Share1.146 GBp
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 GBp
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Target (Mean)1700.00 GBp
Target Range1600.00 GBp – 1800.00 GBp
# Analysts2
Ownership
Shares Out.15.48M
Float5.70M
Insiders60.58%
Institutions14.21%
Technical
SMA 50488.88 (+12.5%)
SMA 200635.65 (-13.5%)
Beta0.87
S&P 52W Chg27.94%
Avg Vol (30d)1.52K
Avg Vol (10d)1.84K
Technical Indicators
RSI (14)68.3
MACD1.6339
MACD Signal-7.6198
MACD Hist.+9.2537
BB Upper530.13 GBp
BB Middle470.57 GBp
BB Lower411.02 GBp
BB Width25.31%
ATR (14)59.60 GBp
Vol Ratio (20d)2.46x